학술논문
Soluble vascular endothelial growth factor receptor 2 and prognosis in patients with chronic heart failure
Document Type
article
Author
Moritake Iguchi; Hiromichi Wada; Tsuyoshi Shinozaki; Masahiro Suzuki; Yoichi Ajiro; Morihiro Matsuda; Akihiro Koike; Tomomi Koizumi; Masatoshi Shimizu; Yujiro Ono; Takashi Takenaka; Satoru Sakagami; Yukiko Morita; Kazuteru Fujimoto; Kazuya Yonezawa; Kazuro Yoshida; Akiyo Ninomiya; Toshihiro Nakamura; Junichi Funada; Yutaka Kajikawa; Yoshifumi Oishi; Toru Kato; Kazuhiko Kotani; Mitsuru Abe; Masaharu Akao; Koji Hasegawa; for the PREHOSP‐CHF Study Investigators
Source
ESC Heart Failure, Vol 8, Iss 5, Pp 4187-4198 (2021)
Subject
Language
English
ISSN
2055-5822
Abstract
Abstract Aims Endothelial cell vascular endothelial growth factor receptor 2 (VEGFR‐2) plays a pivotal role in angiogenesis, which induces physiological cardiomyocyte hypertrophy via paracrine signalling between endothelial cells and cardiomyocytes. We investigated whether a decrease in circulating soluble VEGFR‐2 (sVEGFR‐2) levels is associated with poor prognosis in patients with chronic heart failure (HF). Methods and results We performed a multicentre prospective cohort study of 1024 consecutive patients with HF, who were admitted to hospitals due to acute decompensated HF and were stabilized after initial management. Serum levels of sVEGFR‐2 were measured at discharge. Patients were followed up over 2 years. The outcomes were cardiovascular death, all‐cause death, major adverse cardiovascular events (MACE) defined as a composite of cardiovascular death and HF hospitalization, and HF hospitalization. The mean age of the patients was 75.5 (standard deviation, 12.6) years, and 57% were male. Patients with lower sVEGFR‐2 levels were older and more likely to be female, and had greater proportions of atrial fibrillation and anaemia, and lower proportions of diabetes, dyslipidaemia, and HF with reduced ejection fraction (